Dermatol. praxi. 2013;7(3):121-122

News in onychomycosis treatment

doc.MUDr.Ivana Kuklová, CSc.
Dermatovenerologická klinika 1. LF UK a VFN, Praha

The prevalence of onychomycosis varies from 4 to 18 percent depending upon the age and population studied. Toenail onychomycosis

is most commonly due to dermatophytes; fingernail onychomycosis is more likely than toenail onychomycosis to be due to yeast. The

main systemic drugs approved and widely used for the treatment of onychomycosis are allylamines and azoles. Systemic medications

can be given continually or in a pulsed manner. Therapeutic outcome with ciclopirox and amorolfine lacquers alone and combined with

systemic therapy are also reviewed.

Keywords: onychomycosis, systemic therapy, local therapy

Published: November 1, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kuklová I. News in onychomycosis treatment. Dermatol. praxi. 2013;7(3):121-122.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Kumar S, Kimball AB. New antifungal therapies for the treatment of onychomycosis. Expert Opin Investig Drugs 2009; 18: 727-734. Go to original source... Go to PubMed...
    2. Welsh O, Vera-Cabrera L, Welsh E. Onychomycosis. Clin Dermatol. 2010; 28(2): 151-159. Go to original source... Go to PubMed...
    3. Gupta AK, Schouten JR, Lynch LE. Ciclopirox nail lacquer 8% for the treatment of onychomycosis: a Canadian perspective. Skin Therapy Lett; 2005; 10: 1-3.
    4. Lecha M. Amorolfine and itraconazole combination for severe toenail onychomycosis; results of an open randomized trial in Spain. Br J Dermatol 2001; 145(Suppl 60): 21-26. Go to original source...
    5. Baran R, Kaoukhov A. Topical antifungal drugs for the treatment of onychomycosis: an overview of current strategies for monotherapy and combination therapy. J Eur Acad Dermatol Venereol 2005; 19: 21-29. Go to original source... Go to PubMed...
    6. Gupta AK, Lynde CW, Konnikov N. Single-blind, randomized, prospective study of sequential itraconazole and terbinafine pulse compared with terbinafine pulse for the treatment of toenail onychomycosis. J Am Acad Dermatol 2001; 44: 485-491. Go to original source... Go to PubMed...
    7. Nair AB, Kim HD, Chakraborty B, et al. Ungual and trans-ungual iontophoretic delivery of terbinafine for the treatment of onychomycosis. J Pharm Sci 2009; 98: 4130-4140. Go to original source... Go to PubMed...
    8. Watanabe D, Kawamura C, Masuda Y, Akita Y, Tamada Y, Matsumoto Y. Successful treatment of toenail onychomycosis with photodynamic therapy. Arch Dermatol 2008; 144: 19-21. Go to original source... Go to PubMed...
    9. Piraccini BM, Rech G, Tosti A. Photodynamic therapy of onychomycosis caused by Trichophyton rubrum. J Am Acad Dermatol 2008; 59(5 Suppl): S75-76. Go to original source... Go to PubMed...
    10. Altshuler GB, Anderson RR, Manstein D, et al. Extended theory of selective photothermolysis. Lasers Surg Med. 2001; 29(5): 416-432. Go to original source... Go to PubMed...
    11. Kozarev J, Vizintin Z. Novel laser therapy in treatment of onychomycosis. J Laser Health Acad. 2010; 1: 1-8.
    12. Kuklová I. Medicína pro praxi. 2011; 8(2): 73-76.

    Return to the content


    Dermatology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.